ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1098

ZCCHC6/TUT7 Negatively Regulates Osterix Activity and Influences Osteoblast-Mediated Regulation of Osteoclastogenesis

Gregory Sondag1, Mohammad Khan1, Mohammad Ansari2, Nazar Hussein1,3, Sara Haynie1, Fayez Safadi1 and Tariq M. Haqqi1, 1Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, 2Anatomy & Neurobiology, Northeast Ohio Medical University, Roostown, OH, 3School of Biomedical Sciences, Kent State University, Kent, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: bone metabolism, osteoblasts and osteoclastogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Biology and Pathology of Bone and Joint - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   Mechanisms associated with intrinsic mRNA regulation are important players in development and disease processes. The terminal uridylyl transferases (TUT) are a family of enzymes involved in the regulation of mRNA turnover and apoptosis-mediated global mRNA decay. However, their role in skeletal homeostasis has not been explored. In this study, we investigated the role of ZCCHC6/ TUT7 in osteogenesis and bone homeostasis in mice.

Methods: RNA and protein expression were analyzed using SYBR green-based qPCR and Western blotting respectively. Osteoblasts (OB) and osteoclasts (OC) were generated following our published protocols. TUT7KO mice were generated by gene targeting and their skeletal phenotype was characterized using DXA, mCT, histology and histochemistry. Osteocalcin (OCN), OPG and RANKL were quantified by ELISA. Promoter activity was assessed by Luciferase assays.

Results:   TUT7 showed an age-dependent differential pattern of expression in osseous tissues with expression being high in calvaria and long bones of newborn mice which declined with aging. Next, we generated TUT7KO mice and characterized their skeletal phenotype. Deletion of TUT7 was not lethal and neonatal TUT7KO mice developed normal similiar to wildtype (WT) littermates. However, at 8 weeks of age TUT7KO mice showed significantly increased bone mass compared to WT as determined by DEXA, mCT, and histomorphometric analyses. Serum analyses revealed an increase in OCN and OPG levels as well as a decrease in RANKL suggesting an overall increase in bone mass. Ex vivo analysis of bone marrow derived osteoprogenitor cells and primary calvarial OBs from TUT7KO mice demonstrated increased matrix mineralization as shown by von Kossa staining. These data suggest that TUT7 plays an important role in OB function. Interestingly, osteoclasts derived from TUT7KO mice showed no significant difference in differentiation and function as determined by TRAP staining and osteoclast activity assay. Co-culture of osteoblast and osteoclast precursors from WT and TUT7KO mice revealed that TUT7KO osteoblasts inhibited the generation of TRAP positive osteoclasts. This suggests that the role of TUT7 in bone homeostasis is predominantly mediated by the osteoblasts. Expression analyses of genes known to be important in osteogenesis showed that constitutive expression of master transcription factor osterix (Osx) was significantly upregulated in OB derived from TUT7KO mice compared to OB derived from WT littermates. Importantly genes known to be regulated by Osx were also expressed at significantly higher levels in OB derived from TUT7 KO mice. Regulation of Osx activity by TUT7 was demonstrated using an Osx reporter activity assay and inhibition of the promoter activity by overexpression of TUT7 in OB derived from TUT7 KO mice.

Conclusion:   Overall, our data demonstrate that TUT7 is a negative regulator of bone formation through suppression of Osx activity in OB and influencing osteoblast-mediated regulation of osteoclastogenesis. This study is the first to demonstrate the role of TUT7 in bone formation and identifies a potential target for therapeutic interventions.


Disclosure: G. Sondag, None; M. Khan, None; M. Ansari, None; N. Hussein, None; S. Haynie, None; F. Safadi, None; T. M. Haqqi, None.

To cite this abstract in AMA style:

Sondag G, Khan M, Ansari M, Hussein N, Haynie S, Safadi F, Haqqi TM. ZCCHC6/TUT7 Negatively Regulates Osterix Activity and Influences Osteoblast-Mediated Regulation of Osteoclastogenesis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/zcchc6tut7-negatively-regulates-osterix-activity-and-influences-osteoblast-mediated-regulation-of-osteoclastogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/zcchc6tut7-negatively-regulates-osterix-activity-and-influences-osteoblast-mediated-regulation-of-osteoclastogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology